Table 3.
Univariate and multivariate Cox proportional hazard models for CSS.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR | P-value | HR | P-value | |
| PS ≥ 1 | 1.96 (1.16–3.32) | 0.0124* | 1.49 (0.78–2.86) | 0.2278 |
| Age ≥ 71 (years) | 2.60 (1.57–4.13) | 0.0002* | 3.11 (1.71–5.64) | 0.0002* |
| cT ≥ 3 | 1.53 (0.91–2.58) | 0.11 | ||
| cN1 (+) | 2.70 (1.61–4.55) | 0.0002* | 2.47 (1.29–4.71) | 0.0062* |
| Hb ≥ 13.1 (g/dL) | 0.64 (0.38–1.08) | 0.0946 | ||
| PSADT < 10 (months) | 2.65 (1.26–5.57) | 0.0102* | ||
| PSADT < 6 (months) | 2.75 (1.66–4.56) | < 0.0001* | ||
| PSADT < 4.65 (months) | 3.72 (2.18–6.37) | < 0.0001* | 3.66 (2.01–6.68) | < 0.0001* |
| PSA ≥ 3.3 (ng/dL) | 1.80 (1.11–2.91) | 0.0167* | 1.52 (0.85–2.72) | 0.1627* |
| NHT vs. vintage | 1.07 (0.66–1.71) | 0.7920 | ||
NHT novel hormonal therapy, cN1 clinical positive pelvic lymph node metastasis, cT stage clinical T stage, Hb hemoglobin, PS performance status, HR hazard ratio, PSA prostate-specific antigen, PSADT PSA doubling time, Vintage vintage androgen receptor antagonist.
*P < 0.05.